Two centuries. Countless innovations. One vision.
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for SpikevaxTM COVID-19 Vaccine in Japan to Moderna
Copyright 1995-2022 Takeda Pharmaceutical Company Limited. All rights reserved.